Abstracts tagged "Disease-modifying antirheumatic drugs"

Abstract Number: 196 • 2012 ACR/ARHP Annual Meeting
Sarcoidosis in Northern New England. Clinical Characteristics and Predictive Factors for More Aggressive Therapy
Alireza Meysami¹, Kevin F. Spratt² and Christopher M. Burns³, ¹Rheumatology, Dartmouth Hitchcock Medical Center, Lebanon, NH, ²Department of Orthopaedic Surgery, Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Dartmouth Medical School, Lebanon, NH
· Background/Purpose: Sarcoidosis is characterized by a variable clinical presentation. DMARDs and biologics have been used for resistant and/or organ-threatening disease. We analyzed the cases…
Abstract Number: 112 • 2012 ACR/ARHP Annual Meeting
Time-Integrated Synovitis Activity Assessed by Power Doppler Ultrasound Significantly Correlates with Radiographic Progression in Rheumatoid Arthritis Patients Treated with Methotrexate Alone but Not in Those Treated with TNF Antagonists
Kei Ikeda, Daiki Nakagomi, Yoshie Sanayama, Mieko Yamagata, Ayako Okubo, Taro Iwamoto, Hirotoshi Kawashima, Kentaro Takahashi and Hiroshi Nakajima, Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan
Background/Purpose: Although a number of studies have shown a higher sensitivity of ultrasound than clinical joint examination in detecting synovitis in patients with rheumatoid arthritis…
Abstract Number: 2662 • 2012 ACR/ARHP Annual Meeting
Tightening up: Musculoskeletal Ultrasound Could Further Individualise Treatment Decisions in Early Rheumatoid Arthritis Patients Treated by a Step-up DMARD Escalation Regimen
James Dale¹, David Purves², Alex McConnachie², Duncan Porter³ and Iain B. McInnes⁴, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Robertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom, ³Rheumatology, Gartnavel General Hospital, Glasgow, United Kingdom, ⁴Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Treat-to-target (T2T) strategies have significantly improved outcomes in early rheumatoid arthritis (RA). Treatment escalation is usually guided by a disease activity score; however, modern…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].